Cue Biopharma Newsroom

Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification

TipRanksMay 16 00:25 ET

Cue Biopharma First Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceMay 11 09:15 ET

Express News | Cue Biopharma Shares Are Trading Lower. The Company Reported Q1 Financial Results

BenzingaMay 10 12:42 ET

Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)

TipRanksMay 10 07:57 ET

Express News | Cue Biopharma Inc - Expect Current Cash and Cash Equivalents to Fund Ops Into First Qtr of 2025

ReutersMay 9 16:37 ET

Cue Biopharma | 10-Q: Quarterly report

Futu NewsMay 9 16:05 ET · Announcements

Express News | Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

ReutersMay 9 16:05 ET

Express News | Cue Biopharma, Inc. Q1 Basic EPS USD -0.25

ReutersMay 9 16:05 ET

Express News | Cue Biopharma, Inc. Q1 Operating Expenses USD 14.385 Million

ReutersMay 9 16:05 ET

Express News | Cue Biopharma, Inc. Q1 Collaboration Revenue USD 1.717 Million

ReutersMay 9 16:05 ET

Express News | Cue Biopharma, Inc. Q1 Net Income USD -12.347 Million

ReutersMay 9 16:05 ET

Cue Biopharma 1Q Loss/Shr 25c >CUE

Cue Biopharma 1Q Loss/Shr 25c >CUE

Dow JonesMay 9 16:05 ET

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea

GlobeNewswireMay 8 08:00 ET

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea

GlobeNewswireMay 7 08:00 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersTwist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out to

BenzingaMay 2 16:31 ET

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T

GlobeNewswireApr 24 10:01 ET

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Yahoo FinanceApr 15 09:55 ET

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings,

BenzingaApr 9 10:01 ET

Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning

TipRanksApr 9 09:35 ET

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Dow JonesApr 9 08:56 ET